HRS 2016 roundup: Leadless pacers at the fore
Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ), aiming to distinguish their respective leadless pacemaker offerings, presented new data last week in San Francisco at the Heart Rhythm Society’s annual meeting. St. Jude said a subset of data from the Leadless II trial showed that its Nanostim device was was successfully retrieved in 14 patients up to 3.2 years after implantation, with no serious adverse events. “We’ve now shown that for patients requiring device upgrades or new leadless pacing options, late retrievability – even up to 3 years – is possible with the Nanostim leadless pacemaker,” lead investigator Dr. Vivek Reddy, of New York City’s Mount Sinai Hospital, said in prepared remarks. Leadless II also compared a 718-patient Nanostim-implanted group with a cohort of 10,521 patients implanted with traditional transvenous pacers, using data from Truven MarketScan tracking of healthcare claims and Medicare supplemental insurance encounters. Acute complications occurred in 5.8% of the Nanostim group, compared with 12.7% of patients in the traditional pacer arm. Mid-term complications in the 1st 2 years after implantation were 0.6% for the Nanostim arm and 5.4% for the TVP arm, the Leadless II data showed. “Real-world claims data indicate higher-than-previously-reported rates of TVP complications with clear advantages for LCPs among infectious and lead-related events...
Authors: Bonios MJ, Adamopoulos SN, Drakos SG PMID: 32464278 [PubMed - as supplied by publisher]
CONCLUSION: In hypertensive and diabetic patients, higher OPG values were associated with impaired LA function assessed by 2D-STE. In this high-risk patient group, serum OPG can be used as a risk predictor for LA mechanical dysfunction. PMID: 32462219 [PubMed - as supplied by publisher]
Bipolar disorder has long been associated with increased risks for suicidality; though factors associated with dying by suicide remain obscure. Here, we retrospectively examine the associations between the different phases of bipolar illness and other comm...
PMID: 32463109 [PubMed - in process]
PMID: 32463104 [PubMed - in process]
Philips Wins Regulatory Nod for Clinical Surveillance Biosensor Philips won a nod from FDA and a CE mark for a next-generation wireless wearable biosensor to help monitor COVID-19 patients in hospital. The Amsterdam, Netherlands-based company touts its next-generation device as being able to enhance clinical surveillance in its patient deterioration detection solution to help clinicians detect risk so they can intervene earlier and help improve care in lower acuity care areas. Â Eko Moves Deeper into Telemedicine in the Age of Social Distancing The digital health company is launching a platform that will combin...
Publication date: Available online 29 May 2020Source: IDCasesAuthor(s): Anita Singh, Angel Porras, Francisco Ujueta, Saberio Lo Presti, Nicholas Camps
Publication date: June 2020Source: IJC Heart &Vasculature, Volume 28Author(s): Donato Mele, Gabriele Pestelli, Davide Dal Molin, Andrea Fiorencis, Filippo Flamigni, Giovanni Andrea Luisi, Vittorio Smarrazzo, Filippo Trevisan, Roberto Ferrari
Publication date: June 2020Source: IJC Heart &Vasculature, Volume 28Author(s): Timothy Shih, Karina Ledezma, Mark McCauley, Jalees Rehman, William L. Galanter, Dawood Darbar
More News: Arrhythmia | Atrial Fibrillation | Bipolar | Cardiac Resynchronization Therapy | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clinical Trials | Heart | Heart Failure | Hospital Management | Hospitals | Insurance | Ischemic Stroke | Mania | Medical Devices | Medicare | Nanotechnology | Physiotherapy | Sports Medicine | Stroke | Study | Thrombosis